<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357926</url>
  </required_header>
  <id_info>
    <org_study_id>29-229 ex 16/17</org_study_id>
    <nct_id>NCT03357926</nct_id>
  </id_info>
  <brief_title>Prospective Database for Prediction of Atrial Fibrillation in Pacemaker and ICD Patients</brief_title>
  <acronym>SAFE-ME</acronym>
  <official_title>SAFE-ME - Prospective Database for Prediction of Atrial Fibrillation in Pacemaker and ICD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is associated with a five-fold increased risk of cerebrovascular&#xD;
      stroke. While the risk of stroke in patients with known AF can be calculated via AF stroke&#xD;
      prediction risk scores, the prediction of AF occurrence per se in individual patients remains&#xD;
      difficult.&#xD;
&#xD;
      We will recruit 250 patients with an implanted dual-chamber Pacemaker (PM) or an implantable&#xD;
      cardioverter Defibrillator (ICD) with atrial lead to ensure continuous rhythm monitoring&#xD;
      during follow up. At baseline, we will gather clinical and device data of patients. For AF&#xD;
      prediction based on surface Electrocardiography (ECG), 24-h Holter ECG monitoring will be&#xD;
      performed. After 6 months, we will assess the occurrence of AF during the study period via&#xD;
      interrogation of PM/ICD. The resulting data will be used to develop algorithms including&#xD;
      clinical, device and ECG data for prediction of the development of AF in individual patients.&#xD;
      If possible, we will develop a risk score of high accuracy by combination of demographical,&#xD;
      clinical and technical parameters of device patients. The resulting risk score could&#xD;
      potentially help to facilitate the decision if anticoagulation is necessary in patients with&#xD;
      either risk of AF or embolic stroke of unknown origin. Furthermore, Hayn et al. (AIT Austrian&#xD;
      Institute of Technology) are currently developing algorithms to predict the occurrence of AF&#xD;
      surface ECG data. It is an additional aim of this project to support the development of this&#xD;
      algorithm in pacemaker and ICD patients and to increase the accuracy of AF prediction with&#xD;
      clinical parameters and other parameters available to patients with implanted pacemaker (PM)&#xD;
      or implanted cardioverter-defibrillator (ICD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of occurrence of atrial high rate episodes</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Pacemaker Ddd</condition>
  <condition>ICD</condition>
  <arm_group>
    <arm_group_label>Observation Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>24 hour Holter ECG Monitoring</intervention_name>
    <description>24 hour Holter ECG Monitoring</description>
    <arm_group_label>Observation Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an implanted dual-chamber Pacemaker or an implantable cardioverter&#xD;
        Defibrillator&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Implanted pacemaker or implanted cardioverter defibrillator (ICD) with atrial lead&#xD;
&#xD;
          -  CHADS-VASc Score of 2 or more&#xD;
&#xD;
          -  Sinus rhythm or atrial paced rhythm&#xD;
&#xD;
          -  Atrial stimulation rate 50% or less&#xD;
&#xD;
          -  ModeSwitch rate 50% or less since last pacemaker interrogation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pacemaker or ICD malfunction&#xD;
&#xD;
          -  atrial fibrillation (AF) at time of pacemaker / ICD interrogation&#xD;
&#xD;
          -  AF during 24-hour Holter ECG monitoring&#xD;
&#xD;
          -  permanent AF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Scherr, Assoc.Prof. PD Dr.</last_name>
    <phone>+4331638512544</phone>
    <email>daniel.scherr@medunigraz.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Scherr, Assoc.Prof. PD Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

